Magle Chemoswed Holding Reports Financial Results For Second Quarter 2024
Magle Group's Q2 report highlights organic sales growth and future market expansion with startegic mergers
Q2 2024 KEY INDICATORS
- Revenues amounted to 46.0 MSEK (38.1)
- EBITDA equalled 5.3 MSEK (9.5)
- Operating profit (EBIT) is 1.3 MSEK (6.3)
- Earnings per share SEK 0,0 (0,4) per share
JAN-JUN 2024 KEY INDICATORS
- Revenues amounted to 84.2 MSEK (76.7)
- EBITDA equalled 12.4 MSEK (17.1)
- Operating profit (EBIT) is 5.6 MSEK (10.6)
- Earnings per share SEK 0,3 (0,7) per share
”Magle's Q2 report shows a planned and expected reduction in net profit due to strategic investments in merging Amniotics and PK Chemicals, and resource allocation for DSM product market entry. Organic sales increased in the quarter, demonstrating our underlying strength by maintaining profitability for the period and year, positioning us for long-term growth and market expansion” says Justin Pierce, CEO
